Rituximab (Catalan Wikipedia)

Tandan, Rup; Hehir, Michael K.; Waheed, Waqar; Howard, Diantha B. «Rituximab treatment of miastènia gravis: A systematic review». Muscle & Nerve, 56, 2, 8-2017, p. 185–196. DOI: 10.1002/mus.25597. ISSN: 1097-4598.
Singer, O; McCune, WJ «Update on maintenance therapy for granulomatosi amb poliangiïtis and microscopic polyangiitis.». Current Opinion in Rheumatology, 29, 3, 5-2017, p. 248–253. DOI: 10.1097/BOR.0000000000000382.
«EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts». Pathogens (Basel, Switzerland), 7, 1, 3-2018, p. 28. DOI: 10.3390/pathogens7010028.
«Rituximab in Hodgkin lymphoma: Is the target always a hit?». Cancer Treat Rev, 37, 5, 2011, p. 385–90. DOI: 10.1016/j.ctrv.2010.11.005.
«Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis». N Engl J Med, 350, 25, 2004, p. 2572–81. DOI: 10.1056/NEJMoa032534.
«Advances in rheumatology: new targeted therapeutics». Arthritis Research & Therapy, 13, Suppl 1, 2011, p. S5. DOI: 10.1186/1478-6354-13-S1-S5.
McGinley, MP; Moss, BP; Cohen, JA «Safety of monoclonal antibodies for the treatment of multiple sclerosis.». Expert Opinion on Drug Safety, 16, 1, 1-2017, p. 89–100. DOI: 10.1080/14740338.2017.1250881.
He, Dian; Guo, Rui; Zhang, Fubo; Zhang, Chao «Rituximab for relapsing-remitting multiple sclerosis». The Cochrane Database of Systematic Reviews, 12, 06-12-2013, p. CD009130. DOI: 10.1002/14651858.CD009130.pub3. ISSN: 1469-493X.
«Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story.». Eur J Intern Med, 26, 9, 8-2015, p. 659–65. DOI: 10.1016/j.ejim.2015.07.021.
«Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory púrpura trombocitopènica idiopàtica». Am. J. Hematol., 78, 4, 4-2005, p. 275–80. DOI: 10.1002/ajh.20276.
«Long-term responses seen with rituximab in patients with ITP». Community Oncology, 4, 2, 2007, pàg. 107. Arxivat de l'original el 2007-09-29. DOI: 10.1016/s1548-5315(11)70061-4. Arxivat 2011-07-24 a Wayback Machine.
«Rituximab for Immune Cytopenia in Adults: idiopathic thrombocytopenic purpura, Autoimmune Hemolytic Anemia, and Evans Syndrome». Mayo Clinic Proceedings, 78, 11, 2003, pàg. 1340–1346. Arxivat de l'original el 2006-03-13. DOI: 10.4065/78.11.1340. PMID: 14601692. Arxivat 2006-03-13 a Wayback Machine.
«Treatment of pèmfig vulgar with Rituximab and Intravenous Immune Globulin». N Engl J Med, 355, 17, 26-10-2006, p. 1772–1779. DOI: 10.1056/nejmoa062930.
«Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients». Arch Neurol, 65, 11, 2008, p. 1443–1448. DOI: 10.1001/archneur.65.11.noc80069.
[2014-05-02] Immunomodulators and Rituximab in the Management of Autoimmune Pancreatitis. DOI 10.3998/panc.2013.20.
Pranzatelli, M. R. «Immunologic and Clinical Responses to Rituximab in a Child with Opsoclonus-Myoclonus Syndrome». Pediatrics, 115, 1, 2004, p. e115–9. DOI: 10.1542/peds.2004-0845.
Khosroshahi, A.; Wallace, Z. S.; Crowe, J. L.; Akamizu, T. «International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease». Arthritis & Rheumatology, 67, 7, 2015, p. 1688–1699. DOI: 10.1002/art.39132.
«Persistence of Autoreactive IgA-Secreting B Cells Despite Multiple Immunosuppressive Medications Including Rituximab». JAMA Dermatol, 151, 6, 2015, p. 646–50. DOI: 10.1001/jamadermatol.2015.59.
Molloy, Eamonn S.; Calabrese, Leonard H. «leucoencefalopatia multifocal progressiva associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies». Arthritis & Rheumatism, 64, 9, 2012, p. 3043–3051. DOI: 10.1002/art.34468.
«Interstitial pneumonitis related to rituximab therapy». N Engl J Med, 348, 26, 2003, p. 2690–1; discussion 2690–1. DOI: 10.1056/NEJM200306263482619.
Kriston, Levente «Challenges in Reporting Meta-analyses of Diagnostic Accuracy Studies». Annals of Internal Medicine, 150, 6, 2009, p. 430. DOI: 10.7326/0003-4819-150-6-200903170-00025.
Seyfizadeh, Narges «A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections.». Crit Rev Oncol Hematol, 97, 2016, p. 275–290. DOI: 10.1016/j.critrevonc.2015.09.001.
Rudnicka, D.; Oszmiana, A.; Finch, D. K.; Strickland, I. «Scientists discover why a specific cancer drug is so effective». Blood, 121, 23, 2013, p. 4694–4702. Arxivat de l'original el 2013-05-03. DOI: 10.1182/blood-2013-02-482570.
Rudnicka, D.; Oszmiana, A.; Finch, D. K.; Strickland, I. «Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity». Blood, 121, 23, 2013, p. 4694–4702. DOI: 10.1182/blood-2013-02-482570.
Shaw, T. «B cell therapy for rheumatoid arthritis: The rituximab (anti-CD20) experience». Annals of the Rheumatic Diseases, 62, 90002, 2003, p. 55ii–59. DOI: 10.1136/ard.62.suppl_2.ii55.
Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M. «The epitope recognized by rituximab». Blood, 108, 6, 2006, p. 1975–1978. DOI: 10.1182/blood-2006-04-014639.
«IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma». Blood, 90, 6, 9-1997, pàg. 2188–95. Arxivat de l'original el 2020-03-20. DOI: 10.1182/blood.V90.6.2188. PMID: 9310469 [Consulta: 9 febrer 2021].
Scott, Shane D. «Rituximab: A New Therapeutic Monoclonal Antibody for Non-Hodgkin's Lymphoma». Cancer Practice, 6, 3, 1998, p. 195–197. DOI: 10.1046/j.1523-5394.1998.006003195.x.
Fluge, Øystein; Rekeland, Ingrid G.; Lien, Katarina; Thürmer, Hanne «B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial» (en anglès). Annals of Internal Medicine, 170, 9, 02-04-2019, p. 585–593. DOI: 10.7326/M18-1451. ISSN: 0003-4819.
Castro-Marrero, Jesus; Sáez-Francàs, Naia; Santillo, Dafna; Alegre, Jose «Treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis: All roads lead to Rome». British Journal of Pharmacology, 174, 5, 2017, p. 345–369. DOI: 10.1111/bph.13702.
Bonnan, M; Ferrari, S; Bertandeau, E; Demasles, S «Intrathecal rituximab therapy in multiple sclerosis: review of evidence supporting the need for future trials.». Current Drug Targets, 15, 13, 2014, p. 1205–14. DOI: 10.2174/1389450115666141029234644.

drugbank.ca

DrugBank DB00073 Arxivat 2014-01-05 a Wayback Machine.

drugs.com

«Rituximab». The American Society of Health-System Pharmacists. Arxivat de l'original el 27 març 2016.
«Rituximab Use During Pregnancy», 16-12-2019.

fda.gov

«Boxed Warning and new recommendations to decrease risk of hepatitis B», 13-01-2017.
(18 desembre 2006). "FDA Warns of Safety Concern Regarding Rituxan in New Patient Population". Nota de premsa.
«Rituximab (marketed as Rituxan) Information», 23-07-2015. Arxivat de l'original el 15 novembre 2009.
«Rituximab, RA and PML». Arxivat de l'original el 2008-09-16.
(28 novembre 2018). "FDA approves first biosimilar for treatment of adult patients with non-Hodgkin's lymphoma". Nota de premsa.

gabionline.net

«Biosimilars of Rituximab» (en anglès britànic). Generics and Biosimilars Initiative, 14-04-2017. Arxivat de l'original el 2017-03-31.

genengnews.com

«Roche Gets EC Nod for Follicular Lymphoma Maintenance Therapy». , 29-10-2010.

google.cat

books.google.cat

Bosch, Xavier; Ramos-Casals, Manuel; Khamashta, Munther A. Drugs Targeting B-Cells in malaltia autoimmunes (en anglès). Springer Science & Business Media, 2013, p. 1–4. ISBN 9783034807067.

kurzweilai.net

Rudnicka, D.; Oszmiana, A.; Finch, D. K.; Strickland, I. «Scientists discover why a specific cancer drug is so effective». Blood, 121, 23, 2013, p. 4694–4702. Arxivat de l'original el 2013-05-03. DOI: 10.1182/blood-2013-02-482570.

mayoclinicproceedings.com

«Rituximab for Immune Cytopenia in Adults: idiopathic thrombocytopenic purpura, Autoimmune Hemolytic Anemia, and Evans Syndrome». Mayo Clinic Proceedings, 78, 11, 2003, pàg. 1340–1346. Arxivat de l'original el 2006-03-13. DOI: 10.4065/78.11.1340. PMID: 14601692. Arxivat 2006-03-13 a Wayback Machine.

medscape.com

«Rituximab Biosimilars Shown to Be Safe and Effective». Arxivat de l'original el 15 març 2018.
Tucker, Miriam E. «Rituximab Fails to Improve Symptoms in ME/CFS», 02-04-2019.

nih.gov

dailymed.nlm.nih.gov

«Rituxan- rituximab injection, solution», 06-11-2019.
«Rituxan Hycela- rituximab and hyaluronidase injection, solution», 03-12-2019.

ncbi.nlm.nih.gov

«Rituximab for Immune Cytopenia in Adults: idiopathic thrombocytopenic purpura, Autoimmune Hemolytic Anemia, and Evans Syndrome». Mayo Clinic Proceedings, 78, 11, 2003, pàg. 1340–1346. Arxivat de l'original el 2006-03-13. DOI: 10.4065/78.11.1340. PMID: 14601692. Arxivat 2006-03-13 a Wayback Machine.
«IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma». Blood, 90, 6, 9-1997, pàg. 2188–95. Arxivat de l'original el 2020-03-20. DOI: 10.1182/blood.V90.6.2188. PMID: 9310469 [Consulta: 9 febrer 2021].

northwestern.edu

Paul, Marla. «Popular Cancer Drug Linked to Often Fatal 'Brain Eating' Virus». Northwestern University News and Information, 20-05-2009. Arxivat de l'original el 29 maig 2010.

ophthalmologyjournaloftheaao.com

«Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy». Arxivat de l'original el 2017-08-22.

pancreapedia.org

[2014-05-02] Immunomodulators and Rituximab in the Management of Autoimmune Pancreatitis. DOI 10.3998/panc.2013.20.

reuters.com

; Osterman, Cynthia «Novartis abandons effort for U.S. approval of biosimilar rituximab». Reuters, 02-11-2018.

roche.com

«MabThera SC / Rituxan Hycela (rituximab hyaluronidase)». Arxivat de l'original el 3 d’agost 2020.

rochecanada.com

«Reports of Bowel Obstruction and Perforation with RITUXAN (rituximab)». Roche Canada, 10-11-2006. Arxivat de l'original el 2014-03-27. [Consulta: 9 febrer 2021].

time.com

Saporito, Bill. «Hospitals Furious at Cancer-Drug Price Hikes». Time, 27-10-2014. Arxivat de l'original el 20 octubre 2015.

web.archive.org

«Rituximab». The American Society of Health-System Pharmacists. Arxivat de l'original el 27 març 2016.
«MabThera SC / Rituxan Hycela (rituximab hyaluronidase)». Arxivat de l'original el 3 d’agost 2020.
Paul, Marla. «Popular Cancer Drug Linked to Often Fatal 'Brain Eating' Virus». Northwestern University News and Information, 20-05-2009. Arxivat de l'original el 29 maig 2010.
«Long-term responses seen with rituximab in patients with ITP». Community Oncology, 4, 2, 2007, pàg. 107. Arxivat de l'original el 2007-09-29. DOI: 10.1016/s1548-5315(11)70061-4. Arxivat 2011-07-24 a Wayback Machine.
«Rituximab for Immune Cytopenia in Adults: idiopathic thrombocytopenic purpura, Autoimmune Hemolytic Anemia, and Evans Syndrome». Mayo Clinic Proceedings, 78, 11, 2003, pàg. 1340–1346. Arxivat de l'original el 2006-03-13. DOI: 10.4065/78.11.1340. PMID: 14601692. Arxivat 2006-03-13 a Wayback Machine.
«Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy». Arxivat de l'original el 2017-08-22.
«Reports of Bowel Obstruction and Perforation with RITUXAN (rituximab)». Roche Canada, 10-11-2006. Arxivat de l'original el 2014-03-27. [Consulta: 9 febrer 2021].
«Rituximab (marketed as Rituxan) Information», 23-07-2015. Arxivat de l'original el 15 novembre 2009.
«Rituximab, RA and PML». Arxivat de l'original el 2008-09-16.
Rudnicka, D.; Oszmiana, A.; Finch, D. K.; Strickland, I. «Scientists discover why a specific cancer drug is so effective». Blood, 121, 23, 2013, p. 4694–4702. Arxivat de l'original el 2013-05-03. DOI: 10.1182/blood-2013-02-482570.
DrugBank DB00073 Arxivat 2014-01-05 a Wayback Machine.
«IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma». Blood, 90, 6, 9-1997, pàg. 2188–95. Arxivat de l'original el 2020-03-20. DOI: 10.1182/blood.V90.6.2188. PMID: 9310469 [Consulta: 9 febrer 2021].
Saporito, Bill. «Hospitals Furious at Cancer-Drug Price Hikes». Time, 27-10-2014. Arxivat de l'original el 20 octubre 2015.
«EU approves second indication for subcutaneous form of Roche's rituximab». Arxivat de l'original el 2016-06-07.
«Biosimilars of Rituximab» (en anglès britànic). Generics and Biosimilars Initiative, 14-04-2017. Arxivat de l'original el 2017-03-31.

worldcat.org

Tandan, Rup; Hehir, Michael K.; Waheed, Waqar; Howard, Diantha B. «Rituximab treatment of miastènia gravis: A systematic review». Muscle & Nerve, 56, 2, 8-2017, p. 185–196. DOI: 10.1002/mus.25597. ISSN: 1097-4598.
He, Dian; Guo, Rui; Zhang, Fubo; Zhang, Chao «Rituximab for relapsing-remitting multiple sclerosis». The Cochrane Database of Systematic Reviews, 12, 06-12-2013, p. CD009130. DOI: 10.1002/14651858.CD009130.pub3. ISSN: 1469-493X.
Fluge, Øystein; Rekeland, Ingrid G.; Lien, Katarina; Thürmer, Hanne «B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial» (en anglès). Annals of Internal Medicine, 170, 9, 02-04-2019, p. 585–593. DOI: 10.7326/M18-1451. ISSN: 0003-4819.